Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion to Present at Oppenheimer’s 32nd Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
March 14, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

Biomea to present preclinical data from multiple in vivo studiesBiomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half of 2022, subject to submission and...
March 08, 2022 18:15 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022

Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade B-cell lymphoma and multiple myeloma (MM) preclinical patient derived ex vivo...
February 28, 2022 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Phase I trial of BMF-219, an irreversible covalent menin inhibitor, is currently underway Plan to initiate trials of BMF-219 in up to seven solid and liquid tumor types and diabetes Plan to announce...
February 01, 2022 06:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer

Renowned physician-scientist’s groundbreaking work led to the discovery and characterization of multiple oncogenes, including anaplastic lymphoma kinase (ALK)Dr. Morris will lead clinical development...
January 25, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed

BMF-219 is the first irreversible covalent menin inhibitor to enter the clinicPhase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A gene...
January 11, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference

REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
January 10, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219

REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
January 06, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
January 04, 2022 13:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...